Protembis – a privately-held emerging cardiovascular medical device company – announced the completion of a €30 million Series B funding round for supporting the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).
This funding round was structured in two separate increases in capital, which have both been completed. The funding was co-led by a European consortium of VC investors, including Segulah Medical Acceleration, XGEN Venture, and TechVision Fund. The other investors include Coparion, several large family offices, angel investors, and a multinational medical device strategy.
Protembis also announced the addition of Keith D. Dawkins, MD, to the Board of Directors. Dr. Dawkins has more than 35 years of experience in the cardiovascular environment and has been a practicing interventional cardiologist in the UK for more than 20 years. He has held research roles as a Fulbright Scholar at Stanford University, served as President of the British Cardiovascular Intervention Society, and authored more than 750 academic publications and presentations.
Dr Dawkins was the Chief Medical Officer (CMO) of Shockwave since 2019, and this was preceded by his role as Global CMO at Boston Scientific where he had senior positions since 2008. And he also serves as a member of the boards of Ventric Health LLC and JenaValve Technology and Chairman of InnovHeart s.r.l. Dr Dawkins will contribute his expertise to the clinical strategies of Protembis and the pre-commercial programs as the IDE study concludes.
KEY QUOTES:
“We are delighted to announce the completion of the round and would like to thank our existing investors as well as the new investors for their trust and confidence. It reflects the fact that the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement.”
– Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis
“To have such a visionary leader as Dr Dawkins join our Board of Directors is an exciting indication of the opportunities that cerebral embolic protection holds for future transcatheter therapies. We look forward to close collaboration as the field develops and our superiority trial gains momentum.”
– Azin Parhizgar, PhD, Chairwoman of the Board of Directors
“As a long-term believer in the need to protect the brain from all new lesions during transcatheter aortic valve replacement, I am very pleased to join Protembis. The ProtEmbo System and the clinical trial design are both novel and I am confident that they will be highly disruptive to the field of cerebral embolic protection, removing or mitigating many of the current issues that concern the physician community.”
– Dr. Dawkins
